Friday, June 9, 2023
This activity is intended for primary care physicians, nurse practitioners, physician assistants, and other healthcare professionals, including nurses, who provide care to cancer survivors.
The goal of this activity is to increase awareness of Institute of Medicine (IOM) recommendations for cancer survivorship planning and survivor care and provide relevant clinical content for primary care clinicians.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this enduring material for a maximum of 1.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
processing....
Lifetime risk. For women born today, the lifetime risk for a diagnosis of breast cancer is 1 in 8.[5]
Mortality. The age-adjusted mortality rate for both sexes is 14.3 per 100,000 (95% CI, 14.2-14.3). The age adjusted mortality rate for males is 0.3 per 100,000 (95% CI, 0.3-0.3).[12]
Incidence. All races, age-adjusted incidence rate for both genders is 68.0 per 100,000 (95% CI, 67.9-68.1). The age-adjusted incidence rate for males is 1.4 per 100,000 (95% CI, 1.3-1.4).[10] The leveling of breast cancer incidence since 2003 is attributable to reduced usage of combined estrogen and progestin therapies. However, as the NCI has noted, in situ breast cancer incidence has risen in black women 1.6% since 1998.[5]
Prevalence. According to the National Cancer Institute, there were approximately 2,632,005 breast cancer survivors alive on January 1, 2008.[5]
Lifetime risk. The lifetime risk for prostate cancer is 1 in 6 (16.22%) for a man born today.[5]
Mortality. The 5-year survival rate for prostate cancer (all ages) is 99.4%.[13] Prostate cancer is the second leading cause of cancer death in American men. About 1 in 36 men will die of prostate cancer or about 33, 720 in 2011 out of 240,890 newly diagnosed cases.[14]
Incidence. The estimated age-adjusted incidence rate is 159.6 per 100,000 (95% CI, 159.4-159.9).[10] Incidence rates are disproportionate for race, with the rate for black men (233.8 per 100,000) much higher than that of white men (149.5 per 100,000). The lowest incidence is found in American Indians and Alaskan natives (75.3 per 100,000 men).[5]
Prevalence. On January 1, 2008, in the United States there were approximately 2,355,464 men alive who had a history of cancer of the prostate.[5]
Lifetime risk. One in 20 men and women (5.12%) will be diagnosed with cancer of the colon and rectum during their lifetime.[5]
Mortality. The American Cancer Society estimates 49,380 deaths from colorectal cancer in 2011, 25,250 men and 24,130 women.[9]
Incidence. The age-adjusted incidence rate for all races and both genders for colon and rectum cancer is 50.9 per 100,000 (95% CI, 50.8-51.0). This rate does not include in situ.[10]
Prevalence. According to the NCI, there were approximately 1,110,077 colorectal cancer survivors alive on January 1, 2008, including 542,127 men and 567,950 women.[14]
Lifetime risk. Lymphomas are the most common hematologic malignancy in the United States. NHL comprises 85% of all lymphomas.[15] NHL is the 8th most frequently diagnosed cancer type in the United States.[4] The lifetime risk for a NHL diagnosis is 1 in 48 persons.[5]
Mortality. The age-adjusted mortality rate for NHL is 7.5 per 100,000 (95% CI: 7.4-7.5).[10] Mortality from the disease has decreased significantly for men and women ( 3.0% and 3.755 per year, respectively).[10] While 5-year relative survival for 2001-2007 is estimated at 67.3%, the rate varies by gender and race (66.7% for white men; 69.3% for white women; 55.8% for black men; and 64.8% for black women).[5] The differences for African Americans are attributable to access to care and tumor.[9]
Incidence. It is estimated that 66,360 new cases (36,060 males/30,300 females) will be diagnosed in 2011, representing 4% of all cancer diagnoses.[9] Age-adjusted incidence rates for the United States is 19.4 per 100,000 (95% CI: 19.3-19.4).[10]
Prevalence. On January 1, 2008, there were approximately 454,378 people alive who had a history of NHL (235,433 men and 218,945 women).[5]
